ReviewClinical therapeutics2004
Rosuvastatin in the management of hyperlipidemia.
Review in Clinical therapeutics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04862962 (Retrospective Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin / Ezetimibe as a Treatment for Patients With Dyslipidaemia in Usual Medical Practice.), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin / Ezetimibe as a Treatment for Patients With Dyslipidaemia in Usual Medical Practice.
Who cites it
13 citing papers in PubMed, 69 citations in OpenAlex.
- More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.Transplantation · 2014 · on this mapTrial
- Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency.Lipids in health and disease · 2010Trial
- Pharmacokinetic comparison between the fixed-dose combination of rosuvastatin/ezetimibe 2.5/10 mg and the co-administration of individual formulations in healthy subjects.Translational and clinical pharmacology · 2025Article
- Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients.Cardiology research and practice · 2022Article
- Effect of polycan, a β-glucan originating fromExperimental and therapeutic medicine · 2015Article
- Analytical study for the charge-transfer complexes of rosuvastatin calcium with π-acceptors.Molecules (Basel, Switzerland) · 2013Article
- Effect of Erythrina variegata seed extract on hyperlipidemia elicited by high-fat diet in wistar rats.Journal of pharmacy & bioallied sciences · 2010Article
- Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study.PLoS medicine · 2010Article
- A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy.Clinical pharmacology : advances and applications · 2010Article
- New options in the treatment of lipid disorders in HIV-infected patients.The open AIDS journal · 2009Article
- Are HIV positive patients resistant to statin therapy?Lipids in health and disease · 2007Article
- Rosuvastatin in elderly patients.Drugs & aging · 2007Review
- Rosuvastatin: an independent analysis of risks and benefits.MedGenMed : Medscape general medicine · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosuvastatin is a new statin indicated to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia.
objectiveThe purpose of this article was to review the pharmacology, clinical efficacy, and tolerability of rosuvastatin as monotherapy and combination therapy for patients with hyperlipidemia.
methodsA literature review was conducted using the search term rosuvastatin to identify English-language peer-reviewed articles and abstracts in the MEDLINE and Current Contents databases (both 1966 to March 2004). Citations from available articles were reviewed for additional references, and selected information from the manufacturer was discussed.
resultsRosuvastatin 10 to 40 mg/d reduced LDL-C by 43% to 63% (P < 0.05). Compared with other statins, rosuvastatin had the highest dose-to-dose potency in lowering LDL-C (reduction of 60% vs 50% with atorvastatin, 40% with simvastatin, 30% with pravastatin or lovastatin, and 20% with fluvastatin) and better efficacy in raising HDL-C (increase of approximately 10% vs approximately 5% with other statins; P < 0.05). Rosuvastatin enabled significantly more patients to achieve the National Cholesterol Education Program (NCEP) goals for LDL-C with lower doses (P < 0.05). Rosuvastatin was well tolerated. Incidences of myopathy and liver function test abnormalities were rare and comparable to those of other statins. Because it is not metabolized by the cytochrome P-450 enzymes, rosuvastatin had fewer clinically significant drug interactions compared with other statins. Studies to assess the effect of rosuvastatin on cardiovascular outcomes are ongoing.
conclusionsClinical studies continue to demonstrate that achieving optimal levels of LDL-C is an important goal in reducing cardiovascular events. Recent evidence suggests the need for an even lower LDL-C goal than that being recommended by the NCEP Based on the studies included in this review, rosuvastatin may help patients achieve optimal goals early with lower dosages, thus reducing the need for dose titration or combination therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.